Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
183
-
Total 13F shares, excl. options
-
129M
-
Shares change
-
-7.88M
-
Total reported value, excl. options
-
$213M
-
Value change
-
-$19M
-
Put/Call ratio
-
0.65
-
Number of buys
-
76
-
Number of sells
-
-65
-
Price
-
$1.65
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q3 2024
220 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2024.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 183 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 129M shares
of 207M outstanding shares and own 62.18% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS LP (23.3M shares), BlackRock, Inc. (14.3M shares), VANGUARD GROUP INC (13M shares), Bellevue Group AG (9.94M shares), Two Seas Capital LP (6.58M shares), GEODE CAPITAL MANAGEMENT, LLC (4.33M shares), STATE STREET CORP (3.85M shares), Meditor Group Ltd (3.79M shares), TWO SIGMA INVESTMENTS, LP (3.63M shares), and TWO SIGMA ADVISERS, LP (3.6M shares).
This table shows the top 183 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.